LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

在参考实验室评估TB-LAMP测定

By LabMedica International staff writers
Posted on 01 May 2018
Print article
图片:LAMP检验的结果显示阳性样本发出绿荧光(图片蒙创新诊断产品基金会惠赐)。
图片:LAMP检验的结果显示阳性样本发出绿荧光(图片蒙创新诊断产品基金会惠赐)。
涂片显微镜检是检测肺结核(TB)的一线检验,其灵敏度不高且波动剧烈,范围在30%到70%之间。在固体培养基上的常规培养法灵敏度为80%-90%,但是需要二至八周才能得到结果。
 
使用核酸扩增检验(NAAT)等分子方法也许能更快得出结果,且灵敏度和特异性高。新颖的环介导恒温扩增(LAMP)是一种诱人的诊断平台,因为它的运行时间不到两小时,只需很少的仪器,用肉眼能看到产生的荧光结果。
 
瑞士日内瓦创新诊断产品基金会(www.finddx.org)的科学家主持了一项大型多中心研究,他们收集了每人的两份痰样,样本来自秘鲁、南非、巴西和越南的参考实验室里有结核症状的参与者。用日本东京荣研化学株式会社(www.eiken.co.jp)的TB-LAMP测定检验每份痰样。参考标准包括四份直接涂片、四份培养物和临床观察结果与放射影像结果。8周后对常规检验阴性结果者进行随访。用美国加利福尼亚州森尼韦尔市Cepheid股份有限公司(www.cepheid.com)的Xpert MTB/RIF测定检测新鲜样本或冷冻样本,与分子检验比对。
 
科研小组在2012年1月到12月共招募了1,036名疑似肺结核的成人。培养法证实了375例结核病例,涉及750份痰样,其中TB-LAMP检测到75.6% (95%置信区间(CI)为71.8–79.4%),包括97.9% (95% CI 96.4–99.4%)的涂片阳性结核样本及46.6% (95% CI 40.6–52.7%)的涂片阴性结核样本。477名培养物阴性者未接受结核处理(954份痰样),他们的特异性为98.7% (95% CI 97.9–99.6%)。0.3%的病例的TB-LAMP检验结果难下定论。
 
该研究的论文发表于2018年3月号的《国际传染病杂志》。作者总结说,这项研究发现TB-LAMP的实验室性能接近Xpert MTB/RIF的性能,建议在目标应用场景下做进一步研究,以评估这些预期优点。采用人工技术也许让TB-LAMP有望以低于自动化技术的成本进入市场。
 
Related Links:

创新诊断产品基金会>>> www.finddx.org

荣研化学株式会社>>> www.eiken.co.jp

Cepheid Inc >>> www.cepheid.com


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more